Literature DB >> 17289817

Chronic GvHD decreases antiviral immune responses in allogeneic BMT.

Mohammad S Hossain1, John D Roback, Brian P Pollack, David L Jaye, Amelia Langston, Edmund K Waller.   

Abstract

Chronic graft-versus-host disease (cGvHD) is associated with functional immunodeficiency and an increased risk of opportunistic infections in allogeneic bone marrow transplantation (BMT). We used a parent to F1 model of allogeneic BMT to test the hypothesis that cGvHD leads to impaired antigen-specific antiviral immunity and compared BM transplant recipients with cGvHD to control groups of allogeneic BM transplant recipients without GvHD. Mice with and without cGvHD received a nonlethal dose of murine cytomegalovirus (MCMV) +100 days after transplantation. Recipients with cGvHD had more weight loss and higher viral loads in the spleen and liver. MCMV infection led to greater than 25-fold expansion of donor spleen-derived MCMV peptide-specific tetramer-positive CD8(+) T cells in blood of transplant recipients with and without cGvHD, but mice with cGvHD had far fewer antigen-specific T cells in peripheral tissues and secondary lymphoid organs. The immunosuppression associated with cGvHD was confirmed by vaccinating transplant recipients with and without cGvHD using a recombinant Listeria expressing MCMV early protein (Lm-MCMV). Secondary adoptive transfer of lymphocytes from donor mice with or without cGvHD into lymphopenic congenic recipients showed that cGvHD impaired tissue-specific homing of antigen-specific T cells. These results indicate that cGvHD causes an intrinsic immunosuppression and explain, in part, the functional immunodeficiency in allogeneic transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289817      PMCID: PMC1885501          DOI: 10.1182/blood-2006-04-017442

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.

Authors:  Robert A Seder; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

2.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.

Authors:  H Einsele; H Hebart; C Kauffmann-Schneider; C Sinzger; G Jahn; P Bader; T Klingebiel; K Dietz; J Löffler; C Bokemeyer; C A Müller; L Kanz
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

3.  Protective effects of hochu-ekki-to, a Chinese traditional herbal medicine against murine cytomegalovirus infection.

Authors:  M S Hossain; H Takimoto; S Hamano; H Yoshida; T Ninomiya; Y Minamishima; G Kimura; K Nomoto
Journal:  Immunopharmacology       Date:  1999-04

4.  Cellular and cytokine effectors of acute graft versus host disease.

Authors:  James L M Ferrara
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.

Authors:  Q Nguyen; R Champlin; S Giralt; K Rolston; I Raad; K Jacobson; C Ippoliti; D Hecht; J Tarrand; M Luna; E Whimbey
Journal:  Clin Infect Dis       Date:  1999-03       Impact factor: 9.079

6.  Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.

Authors:  E K Waller; A M Ship; S Mittelstaedt; T W Murray; R Carter; I Kakhniashvili; S Lonial; J T Holden; M W Boyer
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

Review 7.  Chronic graft-versus-host disease: clinical manifestation and therapy.

Authors:  V Ratanatharathorn; L Ayash; H M Lazarus; J Fu; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

8.  Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants.

Authors:  S Kulkarni; R Powles; J Treleaven; U Riley; S Singhal; C Horton; B Sirohi; N Bhagwati; S Meller; R Saso; J Mehta
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

9.  Characterization of CD4- CD8- CD3+ T-cell receptor-alphabeta+ T cells in murine cytomegalovirus infection.

Authors:  M S Hossain; H Takimoto; T Ninomiya; H Yoshida; K Kishihara; G Matsuzaki; G Kimura; K Nomoto
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

10.  The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo.

Authors:  Marielle C Gold; Michael W Munks; Markus Wagner; Ulrich H Koszinowski; Ann B Hill; Steven P Fling
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

View more
  15 in total

1.  Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.

Authors:  Mojtaba Akhtari; Cynthia R Giver; Zahir Ali; Christopher R Flowers; Charise L Gleason; Christopher D Hillyer; Jonathan Kaufman; H Jean Khoury; Amelia A Langston; Mary Jo Lechowicz; Sagar Lonial; Heather M Renfroe; John D Roback; Mourad Tighiouart; Louette Vaughn; Edmund K Waller
Journal:  Transfusion       Date:  2010-11       Impact factor: 3.157

2.  Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Authors:  Mohammad S Hossain; David L Jaye; Brian P Pollack; Alton B Farris; Malefa L Tselanyane; Ebenezer David; John D Roback; Andrew T Gewirtz; Edmund K Waller
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

3.  Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice.

Authors:  Jian-Ming Li; Lauren Southerland; Mohammad S Hossain; Cynthia R Giver; Ying Wang; Kasia Darlak; Wayne Harris; James Waschek; Edmund K Waller
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

Review 4.  Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management.

Authors:  Arvind R Murali; Subhash Chandra; Zoe Stewart; Bruce R Blazar; Umar Farooq; M Nedim Ince; Jeffrey Dunkelberg
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

5.  CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia.

Authors:  Colleen J Winstead; Cavan S Reilly; James J Moon; Marc K Jenkins; Sara E Hamilton; Stephen C Jameson; Sing Sing Way; Alexander Khoruts
Journal:  J Immunol       Date:  2010-03-31       Impact factor: 5.422

6.  Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.

Authors:  Jian-Ming Li; Mohammad S Hossain; Lauren Southerland; Edmund K Waller
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

7.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

Review 8.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

Review 9.  Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.

Authors:  Ying Lu; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2009-11       Impact factor: 5.742

10.  Targeting PKCθ in alloreactivity and graft-versus-host-disease: unanswered questions and therapeutic potential.

Authors:  Crystina C Bronk; Xue-Zhong Yu; Amer A Beg
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.